Summary
Metformin is tracked by OSMF as an investigational option for Other post-viral syndromes; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. No registered clinical trial in this database tests Metformin specifically in Other post-viral syndromes. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 7 publications for this pair: 7 curated references. Publication years run from 2025 to 2026. Items here are search-derived or curated references rather than classified trial reports; treat them as leads to read, not as graded evidence.
Other Post-Infectious and Post-Viral Syndromes is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 10 candidate agents are logged for Other post-viral syndromes, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | B · Moderate |
|---|---|
| Evidence score | 20.5 (trials 0.0, literature 10.5, tier 10, approved bonus 0.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 7 (7 curated references) |
| Agent type | Drug (Drug (Pharmaceutical)) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Anti-inflammatory; Metabolic / Mitochondrial |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
| Also known as | Metformin |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Metformin to Other post-viral syndromes in the current OSMF trial extract.
Published literature
- Curated reference (OSMF) Metformin and Severe Post-COVID-19 Outcomes Among Individuals With Diabetes Mellitus.2026
- Curated reference (OSMF) Metformin at the Time of COVID-19 Infection and Risk of Long COVID: A Target Trial Emulation Study.2026
- Curated reference (OSMF) Mitochondria-targeted therapy with metformin and MitoQ reduces oxidative stress, improves mitochondrial function, and restores metabolic hom2025
- Curated reference PubMed record PMID 40544605
- Curated reference PubMed record PMID 42988585
- Curated reference PubMed record PMID 42954425
- Curated reference (PACVS Evidence Map) Clinician-diagnosed long COVID halved at 6 months (RR 0.495; 95% CI 0.155–0.995); prevention not treatment; concordance across two independent trialsPACVS Evidence Map
Mechanism and notes
Recorded mechanism or class: Anti-inflammatory; Metabolic / Mitochondrial.
Clinical notes: Prevention signal strong; treatment data mixed/preliminary. 500-2000mg. GI effects, B12. Reasonable metabolic adjunct in overweight PASC patients.
Safety: GI side effects (diarrhea, nausea) common initially. Risk of B12 deficiency long-term; lactic acidosis rare (avoid in severe renal/hepatic disease, contrast).
Dosing in studies: 500–2000 mg/day (extended release often better tolerated); prevention trials used during acute infection ~14 days; treatment studies 8–12+ weeks.
Frequently asked questions
Is Metformin approved for Other post-viral syndromes?
Metformin is tracked by OSMF as an investigational option for Other post-viral syndromes; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Metformin in clinical trials for Other post-viral syndromes?
No registered clinical trial in this database tests Metformin specifically in Other post-viral syndromes. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Metformin in Other post-viral syndromes?
The record for Metformin in Other post-viral syndromes rests on 7 publications without a registered trial. This is a lead for hypothesis generation, not evidence of efficacy. OSMF's existing evidence tier for this pair is B (Moderate), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-11-11. Page built 2026-11-11.